Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $139.0 million as the latest value for Q4 2025.
- For Q4 2025, Total Non-Current Liabilities fell 15.16% year-over-year to $139.0 million; the TTM value through Dec 2025 reached $139.0 million, down 15.16%, while the annual FY2025 figure was $141.0 million, 12.56% down from the prior year.
- Total Non-Current Liabilities hit $139.0 million in Q4 2025 for Ascentage Pharma Group International, down from $163.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $207.7 million in Q4 2023 and bottomed at $139.0 million in Q4 2025.
- Average Total Non-Current Liabilities over 3 years is $170.2 million, with a median of $163.9 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities dropped 21.11% in 2024 and then fell 15.16% in 2025.
- Ascentage Pharma Group International's Total Non-Current Liabilities stood at $207.7 million in 2023, then decreased by 21.11% to $163.9 million in 2024, then dropped by 15.16% to $139.0 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $139.0 million, $163.9 million, and $207.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.